Clinical Trials Logo

Filter by:
NCT ID: NCT05633394 Not yet recruiting - Conduction Defect Clinical Trials

Subcostal Temporary Extravascular Pacing V Study

STEP V
Start date: January 23, 2023
Phase: N/A
Study type: Interventional

The STEP V Study is a prospective, multicenter, acute (in-hospital), single-arm feasibility study. The objective of the study is to evaluate the early safety and performance of the latest AtaCor EV Temporary Pacing Lead System over a two-day use period with Subjects restricted to bedrest. Lead performance will also be evaluated without bedrest restrictions in the limited period shortly before lead removal on the last follow-up day.

NCT ID: NCT05508360 Recruiting - Clinical trials for Degenerative Disc Disease

"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2)

LOPAIN2
Start date: August 22, 2022
Phase: N/A
Study type: Interventional

This study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.

NCT ID: NCT05457673 Completed - Conduction Defect Clinical Trials

Subcostal Temporary Extravascular Pacing IV (STEP IV) Study

STEP IV
Start date: August 17, 2022
Phase: N/A
Study type: Interventional

The STEP IV Study is a prospective, single-center, non-randomized, single-arm study without concurrent or historical controls. The objective of the study is to generate safety and performance data of the latest AtaCor EV Temporary Pacing Lead System to support the development of a future pivotal study with an indication limited to a maximum of 7 days.

NCT ID: NCT05426343 Recruiting - COVID-19 Vaccine Clinical Trials

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

Start date: July 9, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to measure the anti-SARS-CoV-2 neutralizing antibody titres in adult participants, in particular elderly, so as to demonstrate immunogenic superiority of MVC-COV1901 to the active control, AZD1222 vaccine, in terms of the GMT of neutralizing antibodies at 14 days after the second dose of the study intervention. This study also assesses the safety and tolerability of the study intervention and explores the immunogenicity in terms of antigen-specific immunoglobulin as well as the potential efficacy of MVC-COV1901 in preventing COVID-19.

NCT ID: NCT05418816 Active, not recruiting - Clinical trials for End Stage Renal Disease

SelfWrap-Assisted Arteriovenous Fistulas

SW-AVF
Start date: June 14, 2021
Phase: N/A
Study type: Interventional

This is a single-center, prospective, single-arm clinical study to evaluate the feasibility, safety, and performance of VenoStent's SelfWrap® Bioabsorbable Perivascular Wrap on arteriovenous fistulas (AVFs). All participants are chronic kidney disease (CKD) patients already receiving hemodialysis treatments that are referred for creation of a new arteriovenous fistula (AVF).

NCT ID: NCT05387811 Recruiting - Acute Kidney Injury Clinical Trials

International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

GLOBAL-AKI
Start date: July 1, 2022
Phase:
Study type: Observational [Patient Registry]

The aims of this study will be to identify the clinical characteristics, the management and the outcomes of acute kidney injury in patients with cirrhosis worldwide. Specific aims: 1. To establish the severity of AKI across different regions 2. To identify precipitants of AKI across different centers 3. To identify the phenotypes of AKI across different centers 4. To evaluate differences in the management of AKI across different centers and their impact on clinical outcomes 5. To assess outcomes of acute kidney injury (resolution of AKI, in-hospital mortality, 28-day mortality, 90-day mortality)

NCT ID: NCT05352776 Completed - Clinical trials for Ventricular Tachycardia

Sensing and Defibrillation With a Commercially Available ICD Coupled With a Parasternal Extravascular Lead (SECURE EV) Study

SECURE EV
Start date: May 18, 2022
Phase: N/A
Study type: Interventional

The SECURE EV Study is a prospective, multi-center, single-arm study without concurrent or historical controls. The objectives of the study are 1) to characterize safety of the AtaCor EV-ICD Lead up to 90 days post-implant, and 2) to characterize sensing and conversion of induced VF up to 90 days post-implant.

NCT ID: NCT05324943 Recruiting - Clinical trials for Gaucher Disease, Type 1

A Gene Therapy Study in Patients With Gaucher Disease Type 1

GALILEO-1
Start date: April 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a first-in-human, phase 1/2, open-label, safety, tolerability, and efficacy study in adult patients with Gaucher disease Type 1. The aims are to investigate the safety/tolerability and efficacy of FLT201, and to investigate the relationship of FLT201 dose to augmentation of residual glucocerebrosidase (GCase) expression (activity and concentration), and its potential to improve the clinical phenotype by reduction and prevention of cellular accumulation of GCase substrate.

NCT ID: NCT05295641 Recruiting - Heart Failure Clinical Trials

American Registry of Ambulatory or Acute Decompensated Heart Failure

AMERICCAASS
Start date: April 1, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to better characterize and understand the population of patients with ambulatory or acutely decompensated heart failure in the American continent, getting to know their sociodemographic, clinical and paraclinical characteristics

NCT ID: NCT05099289 Completed - Clinical trials for Ventricular Tachycardia

Parasternal Access for ShockS and Pacing With an acUtely Placed Less-invasive Lead for EV-ICD (PASS PULL EV-ICD) Study

PASS PULL
Start date: November 17, 2021
Phase: N/A
Study type: Interventional

The PASS PULL EV-ICD Study is a prospective, multi-center, single-arm study without concurrent or historical controls. This initial concept feasibility study is primarily intended to demonstrate that the EV-ICD Lead can be safely positioned within the anterior mediastinum as intended using the AtaCor delivery system. The study will secondarily characterize the ability for the EV-ICD Lead to facilitate VF sensing and defibrillation.